US Congress confirms new drug patent listing law

A $2.3 trillion spending bill passed by the US Congress yesterday, December 21 includes a proposed change to the laws concerning biologic drugs.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Diabetics to benefit under latest FDA biosimilar guidance

13 May 2019 The Food and Drug Administration has issued final guidance on the pathway for ‘interchangeable’ biosimilar products, in a bid to promote competition in the biologics market.

Americas

AstraZeneca asks FDA to delay ANDAs for Crestor generics

14 June 2016 AstraZeneca has filed a citizen petition to the US Food and Drug Administration requesting it to wait until 2023 before approving generic versions of Crestor, a cholesterol treatment.

More features

To disclose or not: Pharma patents face new AI reality

Trade secrets go global: How brand owners face a high-stakes battlefront

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

US Congress confirms new drug patent listing law

More on this story

Editor's picks

Editor's picks

More features